Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies

A Scientific Statement from the American Heart Association

Biykem Bozkurt, Monica Colvin, Jennifer Cook, Leslie T Jr. Cooper, Anita Deswal, Gregg C. Fonarow, Gary S. Francis, Daniel Lenihan, Eldrin F. Lewis, Dennis M. McNamara, Elfriede Pahl, Ramachandran S. Vasan, Kumudha Ramasubbu, Kismet Rasmusson, Jeffrey A. Towbin, Clyde Yancy

Research output: Contribution to journalReview article

87 Citations (Scopus)

Abstract

DCM is an important cause of HF. Characterized by the common phenotype of ventricular dilation and depressed myocardial performance, its pathogenesis varies significantly, ranging from metabolic, endocrine,autoimmune, rheumatologic, infiltrative, genetic, and infectious causes to cardiotoxins. The rapidly expanding field of molecular genetics and diagnostic and biomarker strategies will likely allow us to capture an even better understanding of how cardiomyopathies develop.Demographics and treatment also vary significantly according to the cause. Treatment should be individualized and should target the underlying cause, in addition to the standard systolic HF therapies. In certain cases,with elimination of the cause and the appropriate treatment,reversal of myocardial remodeling and recovery of cardiac dysfunction can occur. Although current clinical research strategies usually target systolic HF as a group, future studies targeting specific cardiomyopathies will be critical for detection and treatment of specific cardiomyopathies.

Original languageEnglish (US)
Pages (from-to)e579-e646
JournalCirculation
Volume134
Issue number23
DOIs
StatePublished - Dec 6 2016

Fingerprint

Dilated Cardiomyopathy
Cardiomyopathies
Cardiotoxins
Molecular Pathology
Molecular Biology
Dilatation
Biomarkers
Demography
Phenotype
Research
Therapeutics

Keywords

  • AHA Scientific Statements
  • cardiomyopathy
  • dilated cardiomyopathy
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies : A Scientific Statement from the American Heart Association. / Bozkurt, Biykem; Colvin, Monica; Cook, Jennifer; Cooper, Leslie T Jr.; Deswal, Anita; Fonarow, Gregg C.; Francis, Gary S.; Lenihan, Daniel; Lewis, Eldrin F.; McNamara, Dennis M.; Pahl, Elfriede; Vasan, Ramachandran S.; Ramasubbu, Kumudha; Rasmusson, Kismet; Towbin, Jeffrey A.; Yancy, Clyde.

In: Circulation, Vol. 134, No. 23, 06.12.2016, p. e579-e646.

Research output: Contribution to journalReview article

Bozkurt, B, Colvin, M, Cook, J, Cooper, LTJ, Deswal, A, Fonarow, GC, Francis, GS, Lenihan, D, Lewis, EF, McNamara, DM, Pahl, E, Vasan, RS, Ramasubbu, K, Rasmusson, K, Towbin, JA & Yancy, C 2016, 'Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association', Circulation, vol. 134, no. 23, pp. e579-e646. https://doi.org/10.1161/CIR.0000000000000455
Bozkurt, Biykem ; Colvin, Monica ; Cook, Jennifer ; Cooper, Leslie T Jr. ; Deswal, Anita ; Fonarow, Gregg C. ; Francis, Gary S. ; Lenihan, Daniel ; Lewis, Eldrin F. ; McNamara, Dennis M. ; Pahl, Elfriede ; Vasan, Ramachandran S. ; Ramasubbu, Kumudha ; Rasmusson, Kismet ; Towbin, Jeffrey A. ; Yancy, Clyde. / Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies : A Scientific Statement from the American Heart Association. In: Circulation. 2016 ; Vol. 134, No. 23. pp. e579-e646.
@article{3f962e54cd7544368a7a58660a0e5efa,
title = "Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association",
abstract = "DCM is an important cause of HF. Characterized by the common phenotype of ventricular dilation and depressed myocardial performance, its pathogenesis varies significantly, ranging from metabolic, endocrine,autoimmune, rheumatologic, infiltrative, genetic, and infectious causes to cardiotoxins. The rapidly expanding field of molecular genetics and diagnostic and biomarker strategies will likely allow us to capture an even better understanding of how cardiomyopathies develop.Demographics and treatment also vary significantly according to the cause. Treatment should be individualized and should target the underlying cause, in addition to the standard systolic HF therapies. In certain cases,with elimination of the cause and the appropriate treatment,reversal of myocardial remodeling and recovery of cardiac dysfunction can occur. Although current clinical research strategies usually target systolic HF as a group, future studies targeting specific cardiomyopathies will be critical for detection and treatment of specific cardiomyopathies.",
keywords = "AHA Scientific Statements, cardiomyopathy, dilated cardiomyopathy, heart failure",
author = "Biykem Bozkurt and Monica Colvin and Jennifer Cook and Cooper, {Leslie T Jr.} and Anita Deswal and Fonarow, {Gregg C.} and Francis, {Gary S.} and Daniel Lenihan and Lewis, {Eldrin F.} and McNamara, {Dennis M.} and Elfriede Pahl and Vasan, {Ramachandran S.} and Kumudha Ramasubbu and Kismet Rasmusson and Towbin, {Jeffrey A.} and Clyde Yancy",
year = "2016",
month = "12",
day = "6",
doi = "10.1161/CIR.0000000000000455",
language = "English (US)",
volume = "134",
pages = "e579--e646",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies

T2 - A Scientific Statement from the American Heart Association

AU - Bozkurt, Biykem

AU - Colvin, Monica

AU - Cook, Jennifer

AU - Cooper, Leslie T Jr.

AU - Deswal, Anita

AU - Fonarow, Gregg C.

AU - Francis, Gary S.

AU - Lenihan, Daniel

AU - Lewis, Eldrin F.

AU - McNamara, Dennis M.

AU - Pahl, Elfriede

AU - Vasan, Ramachandran S.

AU - Ramasubbu, Kumudha

AU - Rasmusson, Kismet

AU - Towbin, Jeffrey A.

AU - Yancy, Clyde

PY - 2016/12/6

Y1 - 2016/12/6

N2 - DCM is an important cause of HF. Characterized by the common phenotype of ventricular dilation and depressed myocardial performance, its pathogenesis varies significantly, ranging from metabolic, endocrine,autoimmune, rheumatologic, infiltrative, genetic, and infectious causes to cardiotoxins. The rapidly expanding field of molecular genetics and diagnostic and biomarker strategies will likely allow us to capture an even better understanding of how cardiomyopathies develop.Demographics and treatment also vary significantly according to the cause. Treatment should be individualized and should target the underlying cause, in addition to the standard systolic HF therapies. In certain cases,with elimination of the cause and the appropriate treatment,reversal of myocardial remodeling and recovery of cardiac dysfunction can occur. Although current clinical research strategies usually target systolic HF as a group, future studies targeting specific cardiomyopathies will be critical for detection and treatment of specific cardiomyopathies.

AB - DCM is an important cause of HF. Characterized by the common phenotype of ventricular dilation and depressed myocardial performance, its pathogenesis varies significantly, ranging from metabolic, endocrine,autoimmune, rheumatologic, infiltrative, genetic, and infectious causes to cardiotoxins. The rapidly expanding field of molecular genetics and diagnostic and biomarker strategies will likely allow us to capture an even better understanding of how cardiomyopathies develop.Demographics and treatment also vary significantly according to the cause. Treatment should be individualized and should target the underlying cause, in addition to the standard systolic HF therapies. In certain cases,with elimination of the cause and the appropriate treatment,reversal of myocardial remodeling and recovery of cardiac dysfunction can occur. Although current clinical research strategies usually target systolic HF as a group, future studies targeting specific cardiomyopathies will be critical for detection and treatment of specific cardiomyopathies.

KW - AHA Scientific Statements

KW - cardiomyopathy

KW - dilated cardiomyopathy

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=85002761027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002761027&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000455

DO - 10.1161/CIR.0000000000000455

M3 - Review article

VL - 134

SP - e579-e646

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -